Biochemical recurrence after localized treatment

The Urologic Clinics of North America
Christopher L Amling

Abstract

The quoted incidence of biochemical recurrence (BCR) after localized treatment varies significantly and depends on numerous well-known prognostic factors; however, it likely occurs in at least 30%-40% of patients who receive localized treatment. Because the clinical significance of BCR is often unclear, and depends in many cases on unknown factors, it is difficult to select the best treatment and determine when best to institute that therapy. This review examines some of the issues associated with BCR and attempts to shed some light on this common but controversial clinical scenario. Some treatment strategies discussed in this article include salvage radiotherapy after radical prostatectomy, salvage therapy after radiotherapy, and hormonal therapy.

References

Jul 15, 1997·International Journal of Radiation Oncology, Biology, Physics·C I SartorH M Sandler
May 11, 1999·JAMA : the Journal of the American Medical Association·C R PoundP C Walsh
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan I IzawaLouis L Pisters
Jul 26, 2002·Urology·Danny Y SongTheodore L DeWeese
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'AmicoDelray Schultz
Feb 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew S KatzSteven A Leibel
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cherry T ThomasRichard L Wahl
Sep 18, 2003·Journal of the National Cancer Institute·Anthony V D'AmicoMing-Hui Chen
Mar 18, 2004·JAMA : the Journal of the American Medical Association·Andrew J StephensonKevin M Slawin
May 6, 2004·The Journal of Urology·Onisuru T OkotieStephen J Freedland
Jul 13, 2004·The New England Journal of Medicine·Anthony V D'AmicoWilliam J Catalona
Jan 12, 2005·The Journal of Urology·Naji J ToumaJoseph L Chin
Mar 11, 2005·The Journal of Urology·John F WardHorst Zincke
Apr 9, 2005·Current Opinion in Urology·Stephen A BrassellDavid G McLeod
May 10, 2005·The Journal of Urology·Deborah A KubanWilliam U Shipley
May 14, 2005·International Journal of Radiation Oncology, Biology, Physics·Fernando J BiancoJames A Eastham
Jul 28, 2005·JAMA : the Journal of the American Medical Association·Stephen J FreedlandAlan W Partin
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'AmicoWilliam J Catalona

❮ Previous
Next ❯

Citations

Feb 10, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·C KansoM Zerbib
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel J CarusoBal L Lokeshwar
Oct 2, 2012·International Journal of Urology : Official Journal of the Japanese Urological Association·Hideaki Miyake, Masato Fujisawa
Mar 28, 2019·Frontiers in Oncology·Katia A CheaitoWassim Abou-Kheir
Mar 19, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Liuyang ZhaoManran Liu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.